| 1 | The role of functional vitamin D deficiency and low vitamin D reservoirs in relation to cardiovascular health and mortality | 2.4 | 5 | Citations (PDF) |
| 2 | Assessing the status of European laboratories in evaluating biomarkers for chronic kidney diseases (CKD) and recommendations for improvement: insights from the 2022 EFLM Task Group on CKD survey | 2.4 | 6 | Citations (PDF) |
| 3 | Diagnostic standard: assessing glomerular filtration rate | 0.8 | 22 | Citations (PDF) |
| 4 | Unveiling a new era with liquid chromatography coupled with mass spectrometry to enhance parathyroid hormone measurement in patients with chronic kidney disease | 5.0 | 12 | Citations (PDF) |
| 5 | In Reply to A Comment about Analytical Performance Specifications for the Combined Measurement Uncertainty Budget in the Implementation of Metrological Traceability of Parathyroid Hormone | 1.1 | 0 | Citations (PDF) |
| 6 | Exploring Renal Function Assessment: Creatinine, Cystatin C, and Estimated Glomerular Filtration Rate Focused on the European Kidney Function Consortium Equation | 2.2 | 36 | Citations (PDF) |
| 7 | Diverse protocols for measuring glomerular filtration rate using iohexol clearance | 0.8 | 1 | Citations (PDF) |
| 8 | Associations of Changes in Bone Turnover Markers with Change in Bone Mineral Density in Kidney Transplant Patients | 4.4 | 14 | Citations (PDF) |
| 9 | Nitrous oxide abuse direct measurement for diagnosis and follow-up: update on kinetics and impact on metabolic pathways | 2.4 | 13 | Citations (PDF) |
| 10 | Performance of an interstitial glucose monitoring device in patients with type 1 diabetes during haemodialysis | 3.6 | 3 | Citations (PDF) |
| 11 | Estimated glomerular filtration rate: applicability of creatinine-based equations in African children | 1.8 | 5 | Citations (PDF) |
| 12 | Familial dysalbuminemic hyperthyroxinemia coexisting with a Grave’s disease: a Belgian case report | 2.4 | 0 | Citations (PDF) |
| 13 | Confounding factors of the expression of mTBI biomarkers, S100B, GFAP and UCH-L1 in an aging population | 2.4 | 7 | Citations (PDF) |
| 14 | Vitamin D: Analytical Advances, Clinical Impact, and Ongoing Debates on Health Perspectives | 1.1 | 19 | Citations (PDF) |
| 15 | Commentary on Understanding Elevated Vitamin D Measurements to Uncover Hypercalcemia Etiology | 1.1 | 0 | Citations (PDF) |
| 16 | Optimisation of vitamin D status in global populations | 4.2 | 21 | Citations (PDF) |
| 17 | A global perspective on the status of clinical metabolomics in laboratory medicine – a survey by the IFCC metabolomics working group | 2.4 | 3 | Citations (PDF) |
| 18 | Performance of creatinine-based equations to estimate glomerular filtration rate in White and Black populations in Europe, Brazil and Africa | 0.8 | 80 | Citations (PDF) |
| 19 | The new, race-free, Chronic Kidney Disease Epidemiology Consortium (CKD-EPI) equation to estimate glomerular filtration rate: is it applicable in Europe? A position statement by the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) | 2.4 | 68 | Citations (PDF) |
| 20 | Determination of parathyroid hormone: from radioimmunoassay to LCMS/MS | 2.4 | 12 | Citations (PDF) |
| 21 | Test results comparison: is the S-Monovette<sup>®</sup> Lithium-Heparin Gel+ a suitable replacement for the S-Monovette<sup>®</sup> Lithium-Heparin Gel on Alinity Abbott<sup>®</sup>? | 2.4 | 0 | Citations (PDF) |
| 22 | New and old GFR equations: a European perspective | 3.6 | 61 | Citations (PDF) |
| 23 | Analytical performance specifications for the measurement uncertainty of 24,25-dihydroxyvitamin D examinations | 2.4 | 6 | Citations (PDF) |
| 24 | Concise review on the combined use of immunocapture, mass spectrometry and liquid chromatography for clinical applications | 2.4 | 7 | Citations (PDF) |
| 25 | International Perspectives on GFR Estimation and Race-Based Adjustments | 1.1 | 2 | Citations (PDF) |
| 26 | Functional Assessment of Vitamin D Status by a Novel Metabolic Approach: The Low Vitamin D Profile Concept | 1.1 | 19 | Citations (PDF) |
| 27 | Lessons from the Belgian experience with regulatory control during the COVID-19 pandemic for the implementation of the European IVD regulation 2017/746 | 1.4 | 3 | Citations (PDF) |
| 28 | Cardiac Biomarkers and Prediction of Early Outcome After Heart Valve Surgery: A Prospective Observational Study | 1.4 | 7 | Citations (PDF) |
| 29 | American Bison (Bison bison) reproductive endocrinology: serum Pregnancy Associated Glycoproteins (PAG), Progesterone, Estrone and Estrone-Sulfate in non pregnant animals and during gestation | 2.1 | 8 | Citations (PDF) |
| 30 | Parathormone, bone alkaline phosphatase and 25-hydroxyvitamin D status in a large cohort of 1200 children and teenagers | 1.4 | 15 | Citations (PDF) |
| 31 | Age-adapted percentiles of measured glomerular filtration in healthy individuals: extrapolation to living kidney donors over 65 years | 2.4 | 9 | Citations (PDF) |
| 32 | Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy | 1.4 | 63 | Citations (PDF) |
| 33 | Comparison of two LC-MS/MS methods for the quantification of 24,25-dihydroxyvitamin D3 in patients and external quality assurance samples | 2.4 | 15 | Citations (PDF) |
| 34 | Arguments for an age-adapted definition of chronic kidney disease | 0.0 | 0 | Citations (PDF) |
| 35 | Albuminuria in diabetic patients: how to measure it?—a narrative review | 0.7 | 9 | Citations (PDF) |
| 36 | P168 Matrix Gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in Crohn’s Disease | 1.3 | 0 | Citations (PDF) |
| 37 | Natural History of Bone Disease following Kidney Transplantation | 0.4 | 22 | Citations (PDF) |
| 38 | Neurofilament light chain concentration in an aging population | 2.9 | 55 | Citations (PDF) |
| 39 | Management of patients at very high risk of osteoporotic fractures through sequential treatments | 2.9 | 93 | Citations (PDF) |
| 40 | Bone Turnover Markers in Children: From Laboratory Challenges to Clinical Interpretation | 2.9 | 24 | Citations (PDF) |
| 41 | Kinetics of Cardiac Remodeling and Fibrosis Biomarkers During an Extreme Mountain Ultramarathon | 2.6 | 7 | Citations (PDF) |
| 42 | Mountain Ultra-Marathon (UTMB) Impact on Usual and Emerging Cardiac Biomarkers | 2.6 | 7 | Citations (PDF) |
| 43 | Analytical evaluation of the Nittobo Medical tartrate resistant acid phosphatase isoform 5b (TRACP-5b) EIA and comparison with IDS iSYS in different clinically defined populations | 2.4 | 8 | Citations (PDF) |
| 44 | Interdisciplinary management of FGF23-related phosphate wasting syndromes: a Consensus Statement on the evaluation, diagnosis and care of patients with X-linked hypophosphataemia | 36.0 | 98 | Citations (PDF) |
| 45 | Estimating urine albumin to creatinine ratio from protein to creatinine ratio using same day measurement: validation of equations | 2.4 | 5 | Citations (PDF) |
| 46 | The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations | 2.9 | 49 | Citations (PDF) |
| 47 | Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club | 4.1 | 71 | Citations (PDF) |
| 48 | Clinical utility of bone turnover markers in patients with chronic kidney disease | 2.3 | 20 | Citations (PDF) |
| 49 | Evolution of 17-β-estradiol, estrone and estrone-sulfate concentrations in late pregnancy of different breeds of mares using Liquid Chromatography and Mass Spectrometry | 2.5 | 8 | Citations (PDF) |
| 50 | Qualitative and quantitative comparison of different commercially available 1–84 parathyroid hormone proteins to the WHO international standard 95/646 using orthogonal methods | 3.1 | 1 | Citations (PDF) |
| 51 | Positive Effects of Vitamin D Supplementation in Patients Hospitalized for COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial | 4.7 | 67 | Citations (PDF) |
| 52 | New Faecal Calprotectin Assay by IDS: Validation and Comparison to DiaSorin Method | 3.0 | 2 | Citations (PDF) |
| 53 | Response to “About the estimation of albuminuria based on proteinuria results” | 2.4 | 0 | Citations (PDF) |
| 54 | Validation of an LC-MS/MS Method Using Solid-Phase Extraction for the Quantification of 1-84 Parathyroid Hormone: Toward a Candidate Reference Measurement Procedure | 1.1 | 27 | Citations (PDF) |
| 55 | Lower Bone Turnover and Skeletal PTH Responsiveness in Japanese Compared to European Patients on Hemodialysis | 4.2 | 13 | Citations (PDF) |
| 56 | Response to Letter to the Editor From Sumi et al: “Lower Bone Turnover and Skeletal PTH Responsiveness in Japanese Compared to European Patients Receiving Hemodialysis” | 4.2 | 0 | Citations (PDF) |
| 57 | Alkaline Phosphatases: Biochemistry, Functions, and Measurement | 2.9 | 106 | Citations (PDF) |
| 58 | The impact of an ultra-trail on the dynamic of cardiac, inflammatory, renal and oxidative stress biological markers correlated with electrocardiogram and echocardiogram | 1.4 | 6 | Citations (PDF) |
| 59 | Cystatin C and Urine Albumin to Creatinine Ratio Predict 5-Year Mortality and Cardiovascular Events in People Living With HIV | 3.8 | 7 | Citations (PDF) |
| 60 | Development and validation of a fast and reliable method for the quantification of glucagon by liquid chromatography and tandem mass spectrometry | 1.6 | 8 | Citations (PDF) |
| 61 | Prediction of 5-year mortality risk by malnutrition according to the GLIM format using seven pragmatic approaches to define the criterion of loss of muscle mass | 5.6 | 30 | Citations (PDF) |
| 62 | Proteinuria in COVID-19: prevalence, characterization and prognostic role | 1.6 | 39 | Citations (PDF) |
| 63 | Analytical Performance Specifications for 25-Hydroxyvitamin D Examinations | 4.7 | 20 | Citations (PDF) |
| 64 | Oxidative Stress Status in COVID-19 Patients Hospitalized in Intensive Care Unit for Severe Pneumonia. A Pilot Study | 5.9 | 126 | Citations (PDF) |
| 65 | YKL-40 as a new promising prognostic marker of severity in COVID infection | 7.8 | 26 | Citations (PDF) |
| 66 | A Multicenter Study to Evaluate Harmonization of Assays for C-Terminal Telopeptides of Type I Collagen (ß-CTX): A Report from the IFCC-IOF Committee for Bone Metabolism (C-BM) | 2.9 | 20 | Citations (PDF) |
| 67 | Consensus Recommendations for the Diagnosis and Management of X-Linked Hypophosphatemia in Belgium | 4.1 | 48 | Citations (PDF) |
| 68 | Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression | 3.6 | 42 | Citations (PDF) |
| 69 | Comparison of Plasma Clearance With Early-Compartment Correction Equations and Urinary Clearance in High GFR Ranges | 2.5 | 9 | Citations (PDF) |
| 70 | Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and β-CTX in blood | 1.6 | 46 | Citations (PDF) |
| 71 | The path to the standardization of PTH: Is this a realistic possibility? a position paper of the IFCC C-BM | 1.6 | 27 | Citations (PDF) |
| 72 | MO523PATIENTS FROM COVID-19 MOSTLY RECOVER FROM TUBULAR PROTEINURIA AND ACUTE KIDNEY INJURY AFTER HOSPITAL DISCHARGE | 0.8 | 0 | Citations (PDF) |
| 73 | Long-term stability of 25-hydroxyvitamin D: importance of the analytical method and of the patient matrix | 2.4 | 11 | Citations (PDF) |
| 74 | FC 076DIAGNOSTIC ACCURACY OF BONE TURNOVER MARKERS IN RENAL OSTEODYSTROPHY | 0.8 | 1 | Citations (PDF) |
| 75 | Non-oxidized parathyroid hormone (PTH) measured by current method is not superior to total PTH in assessing bone turnover in chronic kidney disease | 5.0 | 19 | Citations (PDF) |
| 76 | Development and validation of a liquid chromatography coupled to mass spectrometer (LC-MS) method for the simultaneous quantification of estrone-3-sulfate, progesterone, estrone and estradiol in serum of mares and American bisons | 1.8 | 20 | Citations (PDF) |
| 77 | FC 056ESTIMATING ALBUMIN TO CREATININE RATIO FROM PROTEIN TO CREATININE RATIO USING SAME DAY MEASUREMENT: VALIDATION OF EQUATION | 0.8 | 0 | Citations (PDF) |
| 78 | How can the orthopedic surgeon ensure optimal vitamin D status in patients operated for an osteoporotic fracture? | 4.2 | 15 | Citations (PDF) |
| 79 | Comparison of the Quantitative DiaSorin Liaison Antigen Test to Reverse Transcription-PCR for the Diagnosis of COVID-19 in Symptomatic and Asymptomatic Outpatients | 4.1 | 36 | Citations (PDF) |
| 80 | 2021 revised algorithm for the management of knee osteoarthritis—the Chinese viewpoint | 2.9 | 14 | Citations (PDF) |
| 81 | Recommendations on the measurement and the clinical use of vitamin D metabolites and vitamin D binding protein – A position paper from the IFCC Committee on bone metabolism | 1.6 | 55 | Citations (PDF) |
| 82 | Assessment of serum total 25-hydroxyvitamin D assay commutability of Standard Reference Materials and College of American Pathologists Accuracy-Based Vitamin D (ABVD) Scheme and Vitamin D External Quality Assessment Scheme (DEQAS) materials: Vitamin D Standardization Program (VDSP) Commutability Study 2 | 3.5 | 19 | Citations (PDF) |
| 83 | Effects of various pre-analytical conditions on blood-based biomarkers of Alzheimer’s disease | 2.4 | 0 | Citations (PDF) |
| 84 | Post-intensive care syndrome after a critical COVID-19: cohort study from a Belgian follow-up clinic | 4.8 | 118 | Citations (PDF) |
| 85 | Interlaboratory comparison of 25-hydroxyvitamin D assays: Vitamin D Standardization Program (VDSP) Intercomparison Study 2 — Part 2 ligand binding assays — impact of 25-hydroxyvitamin D2 and 24R,25-dihydroxyvitamin D3 on assay performance | 3.5 | 23 | Citations (PDF) |
| 86 | Interlaboratory comparison of 25-hydroxyvitamin D assays: Vitamin D Standardization Program (VDSP) Intercomparison Study 2 — Part 1 liquid chromatography – tandem mass spectrometry (LC-MS/MS) assays — impact of 3-epi-25-hydroxyvitamin D3 on assay performance | 3.5 | 24 | Citations (PDF) |
| 87 | The « race » correction in estimating glomerular filtration rate: an European point of view | 2.3 | 21 | Citations (PDF) |
| 88 | Mutation of SGK3, a novel regulator of renal phosphate transport, causes autosomal dominant hypophosphatemic Rickets | 0.2 | 1 | Citations (PDF) |
| 89 | Iohexol Plasma Clearance: Impact of Weighing the Syringe | 2.5 | 3 | Citations (PDF) |
| 90 | Vitamin D Standardization Program (VDSP) intralaboratory study for the assessment of 25-hydroxyvitamin D assay variability and bias | 2.4 | 45 | Citations (PDF) |
| 91 | A proposed Common Training Framework for Specialists in Laboratory Medicine under EU Directive 2013/55/EC (The Recognition of Professional Qualifications) | 2.4 | 10 | Citations (PDF) |
| 92 | What does a PTH of 300 pg/mL actually mean? | 0.8 | 2 | Citations (PDF) |
| 93 | Assessment of serum total 25-hydroxyvitamin D assays for Vitamin D External Quality Assessment Scheme (DEQAS) materials distributed at ambient and frozen conditions | 3.5 | 11 | Citations (PDF) |
| 94 | Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis | 2.9 | 62 | Citations (PDF) |
| 95 | Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol | 0.8 | 29 | Citations (PDF) |
| 96 | Vitamin D Supplementation in France in patients with or at risk for osteoporosis: Recent data and new practices | 2.3 | 23 | Citations (PDF) |
| 97 | Detection of wheat allergens using 2D Western blot and mass spectrometry | 3.1 | 12 | Citations (PDF) |
| 98 | The measurement of vitamin D metabolites: part I—metabolism of vitamin D and the measurement of 25-hydroxyvitamin D | 1.9 | 46 | Citations (PDF) |
| 99 | Sclerostin within the chronic kidney disease spectrum | 1.6 | 15 | Citations (PDF) |
| 100 | Bone alkaline phosphatase: An important biomarker in chronic kidney disease – mineral and bone disorder | 1.6 | 102 | Citations (PDF) |
| 101 | Bone biomarkers in de novo renal transplant recipients | 1.6 | 11 | Citations (PDF) |
| 102 | Vitamin D testing: advantages and limits of the current assays | 2.8 | 118 | Citations (PDF) |
| 103 | Simultaneous measurement of 25(OH)-vitamin D and 24,25(OH)2-vitamin D to define cut-offs for CYP24A1 mutation and vitamin D deficiency in a population of 1200 young subjects | 2.4 | 45 | Citations (PDF) |
| 104 | Mutation of SGK3, a Novel Regulator of Renal Phosphate Transport, Causes Autosomal Dominant Hypophosphatemic Rickets | 4.2 | 10 | Citations (PDF) |
| 105 | Vitamin D for the older patient | 3.2 | 1 | Citations (PDF) |
| 106 | Evolution of the slopes of ST2 and galectin-3 during marathon and ultratrail running compared to a control group | 2.4 | 10 | Citations (PDF) |
| 107 | Simultaneous determination of 24,25- and 25,26-dihydroxyvitamin D3 in serum samples with liquid-chromatography mass spectrometry – A useful tool for the assessment of vitamin D metabolism | 2.6 | 37 | Citations (PDF) |
| 108 | Pyruvate dehydrogenase kinase/lactate axis: a therapeutic target for neovascular age-related macular degeneration identified by metabolomics | 3.8 | 19 | Citations (PDF) |
| 109 | The Effects of 6-Month Vitamin D Supplementation during the Non-Surgical Treatment of Periodontitis in Vitamin-D-Deficient Patients: A Randomized Double-Blind Placebo-Controlled Study | 4.7 | 29 | Citations (PDF) |
| 110 | Clinical evidence of direct bone effects of cinacalcet | 5.0 | 9 | Citations (PDF) |
| 111 | The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women | 3.1 | 58 | Citations (PDF) |
| 112 | Mortality in malnourished older adults diagnosed by ESPEN and GLIM criteria in the SarcoPhAge study | 9.3 | 82 | Citations (PDF) |
| 113 | Could KL-6 levels in COVID-19 help to predict lung disease? | 4.5 | 31 | Citations (PDF) |
| 114 | P0186SERUM CYSTATIN C, INFLAMMATION AND AUTONOMIC DYSFUNCTION : A HIDDEN “MÉNAGE À TROIS”? | 0.8 | 0 | Citations (PDF) |
| 115 | How to manage osteoporosis before the age of 50 | 3.1 | 105 | Citations (PDF) |
| 116 | Vitamin D deficiency and the COVID-19 pandemic | 2.4 | 96 | Citations (PDF) |
| 117 | Comparison of Early-Compartment Correction Equations for GFR Measurements | 2.5 | 8 | Citations (PDF) |
| 118 | The percentage of non-oxidized PTH concentration remains stable over a period of 1 year in hemodialyzed patients | 1.6 | 4 | Citations (PDF) |
| 119 | Intense sport practices and cardiac biomarkers | 1.9 | 15 | Citations (PDF) |
| 120 | Harmonization of commercial assays for PINP; the way forward | 4.2 | 18 | Citations (PDF) |
| 121 | European Biological Variation Study (EuBIVAS): within- and between-subject biological variation estimates of β-isomerized C-terminal telopeptide of type I collagen (β-CTX), N-terminal propeptide of type I collagen (PINP), osteocalcin, intact fibroblast growth factor 23 and uncarboxylated-unphosphorylated matrix-Gla protein—a cooperation between the EFLM Working Group on Biological Variation and the International Osteoporosis Foundation-International Federation of Clinical Chemistry Committee on Bone Metabol | 4.2 | 42 | Citations (PDF) |
| 122 | The measurement of vitamin D metabolites part II—the measurement of the various vitamin D metabolites | 1.9 | 13 | Citations (PDF) |
| 123 | Urinary strips for protein assays: easy to do but difficult to interpret! | 1.6 | 15 | Citations (PDF) |
| 124 | The pathway through LC-MS method development: in-house or ready-to-use kit-based methods? | 2.4 | 14 | Citations (PDF) |
| 125 | Cardiovascular Risk in Patients with Primary Hyperparathyroidism | 2.4 | 23 | Citations (PDF) |
| 126 | SUN-LB46 Differences in IGF-I Concentrations Between European and US Populations - Consequences for Reference Intervals | 0.3 | 0 | Citations (PDF) |
| 127 | Management of a global health crisis: first COVID-19 disease feedback from Overseas and French-speaking countries medical biologists | 0.1 | 0 | Citations (PDF) |
| 128 | East meets West: current practices and policies in the management of musculoskeletal aging | 2.9 | 39 | Citations (PDF) |
| 129 | Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO) | 12.0 | 163 | Citations (PDF) |
| 130 | Determination of iohexol by capillary blood microsampling and UHPLC-MS/MS | 7.8 | 14 | Citations (PDF) |
| 131 | Algorithm for the Use of Biochemical Markers of Bone Turnover in the Diagnosis, Assessment and Follow-Up of Treatment for Osteoporosis | 3.5 | 88 | Citations (PDF) |
| 132 | Estimated glomerular filtration rate using a point of care measure of creatinine in patients with iohexol determinate GFR | 1.6 | 18 | Citations (PDF) |
| 133 | Myostatin and Insulin-Like Growth Factor 1 Are Biomarkers of Muscle Strength, Muscle Mass, and Mortality in Patients on Hemodialysis 2019, 29, 511-520 | | 47 | Citations (PDF) |
| 134 | Vitamin D, bone alkaline phosphatase and parathyroid hormone in healthy subjects and haemodialysed patients from West Africa: impact of reference ranges and parathyroid hormone generation assays on the KDIGO guidelines | 3.6 | 7 | Citations (PDF) |
| 135 | A distinct bone phenotype in ADPKD patients with end-stage renal disease | 5.0 | 31 | Citations (PDF) |
| 136 | La supplémentation en vitamine D en France chez les patients ostéoporotiques ou à risque d’ostéoporose : données récentes et nouvelles pratiques | 0.0 | 7 | Citations (PDF) |
| 137 | A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism | 2.4 | 32 | Citations (PDF) |
| 138 | Re-certification of hydroxyvitamin D standards by isotope pattern deconvolution | 2.6 | 3 | Citations (PDF) |
| 139 | Bone mineral density, bone turnover markers, and incident fractures in de novo kidney transplant recipients | 5.0 | 82 | Citations (PDF) |
| 140 | Highly sensitive and selective separation of intact parathyroid hormone and variants by sheathless CE‐ESI‐MS/MS | 2.6 | 21 | Citations (PDF) |
| 141 | Parathyroid hormone results interpretation in the background of variable analytical performance | 0.7 | 11 | Citations (PDF) |
| 142 | Performance of creatinine- or cystatin C–based equations to estimate glomerular filtration rate in sub-Saharan African populations | 5.0 | 90 | Citations (PDF) |
| 143 | Comparison of isotope pattern deconvolution and calibration curve quantification methods for the determination of estrone and 17β-estradiol in human serum | 3.1 | 8 | Citations (PDF) |
| 144 | Comparison of cardiac biomarker dynamics in marathon, semi-marathon and untrained runners: what is the impact on results interpretation? | 0.7 | 9 | Citations (PDF) |
| 145 | Liquid chromatography-tandem mass spectrometry for monitoring vitamin D hydroxymetabolites in human aqueous humor | 2.6 | 6 | Citations (PDF) |
| 146 | Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease | 2.6 | 19 | Citations (PDF) |
| 147 | Preserved wake-dependent cortical excitability dynamics predict cognitive fitness beyond age-related brain alterations | 4.4 | 17 | Citations (PDF) |
| 148 | Estimation of glomerular filtration rate using cystatin C | 0.1 | 8 | Citations (PDF) |
| 149 | Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease | 3.6 | 37 | Citations (PDF) |
| 150 | Poor Vitamin K Status Is Associated With Low Bone Mineral Density and Increased Fracture Risk in End-Stage Renal Disease | 5.0 | 57 | Citations (PDF) |
| 151 | Estimating uncertainty of target values for DEQAS serum materials | 2.4 | 9 | Citations (PDF) |
| 152 | Establishment of reference intervals for serum concentrations of androstanediol glucuronide by a newly developed LC-MS/MS method | 2.0 | 4 | Citations (PDF) |
| 153 | G1 is the major <i>APOL1</i> risk allele for hypertension-attributed nephropathy in Central Africa | 3.6 | 18 | Citations (PDF) |
| 154 | Ultra-high-performance liquid chromatography-mass spectrometry method for neutrophil gelatinase-associated lipocalin as a predictive biomarker in acute kidney injury | 5.9 | 13 | Citations (PDF) |
| 155 | Vitamin D nutritional status and bone turnover markers in childhood acute lymphoblastic leukemia survivors: A PETALE study | 5.6 | 21 | Citations (PDF) |
| 156 | Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones | 1.6 | 9 | Citations (PDF) |
| 157 | Evaluation of a Panel of MicroRNAs that Predicts Fragility Fracture Risk: A Pilot Study | 2.9 | 28 | Citations (PDF) |
| 158 | The first step in creating national Chronic Kidney Disease (CKD) guidelines – a
questionnaire | 1.2 | 3 | Citations (PDF) |
| 159 | Establishment of reference values in a healthy population and interpretation of serum PTH concentrations in hemodialyzed patients according to the KDIGO Guidelines using the Lumipulse® G whole PTH (3rd generation) assay | 1.9 | 13 | Citations (PDF) |
| 160 | Single- versus multiple-sample method to measure glomerular filtration rate | 0.8 | 30 | Citations (PDF) |
| 161 | Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know | 0.8 | 25 | Citations (PDF) |
| 162 | Measured (and estimated) glomerular filtration rate: reference values in West Africa | 0.8 | 26 | Citations (PDF) |
| 163 | Spurious intraoperative PTH results observed with 2 nd , but not with 3 rd generation PTH assays | 1.6 | 6 | Citations (PDF) |
| 164 | Guidelines for the conduct of pharmacological clinical trials in hand osteoarthritis: Consensus of a Working Group of the European Society on Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) | 3.9 | 30 | Citations (PDF) |
| 165 | Urinary protein or albumin/creatinin ratio for reporting measurements results | 0.1 | 0 | Citations (PDF) |
| 166 | Serum creatinine: advantages and pitfalls | 0.7 | 42 | Citations (PDF) |
| 167 | Bone markers and chronic kidney diseases | 0.7 | 10 | Citations (PDF) |
| 168 | Urinary strips for proteins: easy to do but difficult to read! | 0.1 | 0 | Citations (PDF) |
| 169 | Conversion to Graves disease from Hashimoto thyroiditis: a study of 24 patients | 1.4 | 33 | Citations (PDF) |
| 170 | Vitamin D-Resistant Rickets and Cinacalcet—One More Favorable Experience | 1.8 | 12 | Citations (PDF) |
| 171 | Evaluation of the new Sebia free light chain assay using the AP22 ELITE instrument | 1.6 | 16 | Citations (PDF) |
| 172 | Plasma Klotho and Mortality Risk Among Nursing Home Residents: Results From the SENIOR Cohort | 2.4 | 5 | Citations (PDF) |
| 173 | Moving from the second to the third generation Roche PTH assays: what are the consequences for clinical practice? | 2.4 | 14 | Citations (PDF) |
| 174 | FP292MEASUREMENT OF GLOMERULAR FILTRATION RATE BY PLASMA IOHEXOL CLEARANCE WITH DIFFERENT SINGLE-SAMPLE METHODS | 0.8 | 0 | Citations (PDF) |
| 175 | Case report: Uncommon Sulfamethoxazole crystalluria | 1.9 | 5 | Citations (PDF) |
| 176 | Light exposure via a head‐mounted device suppresses melatonin and improves vigilant attention without affecting cortisol and comfort | 1.2 | 14 | Citations (PDF) |
| 177 | Raman chemical imaging, a new tool in kidney stone structure analysis: Case-study and comparison to Fourier Transform Infrared spectroscopy | 2.4 | 38 | Citations (PDF) |
| 178 | A Randomized Study to Compare a Monthly to a Daily Administration of Vitamin D3 Supplementation | 4.7 | 42 | Citations (PDF) |
| 179 | Migration from RIA to LC-MS/MS for aldosterone determination: Implications for clinical practice and determination of plasma and urine reference range intervals in a cohort of healthy Belgian subjects | 1.9 | 16 | Citations (PDF) |
| 180 | Performance of glomerular filtration rate estimation equations in Congolese healthy adults: The inopportunity of the ethnic correction | 2.4 | 51 | Citations (PDF) |
| 181 | Clinical usefulness of bone turnover marker concentrations in osteoporosis | 1.6 | 109 | Citations (PDF) |
| 182 | Supplementation with 80,000 IU vitamin D3/month between November and April corrects vitamin D insufficiency without overdosing: Effect on serum 25-hydroxyvitamin D serum concentrations | 2.7 | 3 | Citations (PDF) |
| 183 | Parathormone stability in hemodialyzed patients and healthy subjects: comparison on non-centrifuged EDTA and serum samples with second- and third-generation assays | 2.4 | 14 | Citations (PDF) |
| 184 | Effect of Body Site and Surface on Vitamin D and 25-Hydroxyvitamin D Production after a Single Narrowband UVB Exposure | 2.3 | 8 | Citations (PDF) |
| 185 | Multicenter Evaluation of Cystatin C Measurement after Assay Standardization | 1.1 | 79 | Citations (PDF) |
| 186 | Biomarkers Predicting Bone Turnover in the Setting of CKD | 4.8 | 38 | Citations (PDF) |
| 187 | Hypercalcémie par mutation inactivatrice du CYP24A1. Étude d’un cas et revue de la littérature | 0.2 | 6 | Citations (PDF) |
| 188 | Relevance of vitamin D in the pathogenesis and therapy of frailty | 3.2 | 51 | Citations (PDF) |
| 189 | Osteoporosis in Frail Patients: A Consensus Paper of the Belgian Bone Club | 2.9 | 45 | Citations (PDF) |
| 190 | Variations of parathyroid hormone and bone biomarkers are concordant only after a long term follow-up in hemodialyzed patients | 3.5 | 4 | Citations (PDF) |
| 191 | A fast and simple method for simultaneous measurements of 25(OH)D, 24,25(OH) 2 D and the Vitamin D Metabolite Ratio (VMR) in serum samples by LC-MS/MS | 1.6 | 45 | Citations (PDF) |
| 192 | Skeletal health in breast cancer survivors | 3.1 | 23 | Citations (PDF) |
| 193 | Evaluation of a New Fully Automated Assay for Plasma Intact FGF23 | 2.9 | 48 | Citations (PDF) |
| 194 | [PP.17.17] ASSOCIATION BETWEEN CIRCULATING LEVELS OF MATRIX-GLA-PROTEIN AND AORTIC STIFFNESS IN KIDNEY TRANSPLANTATION | 2.3 | 1 | Citations (PDF) |
| 195 | Vitamin D and osteosarcopenia | 3.2 | 38 | Citations (PDF) |
| 196 | Distinction between urine crystals by automated urine analyzer SediMAX conTRUST is specific but lacks sensitivity | 2.4 | 6 | Citations (PDF) |
| 197 | Occurrence of Clinical Bone Fracture Following a Prolonged Stay in Intensive Care Unit: A Retrospective Controlled Study | 2.9 | 3 | Citations (PDF) |
| 198 | Perspective and priorities for improvement of parathyroid hormone (PTH) measurement – A view from the IFCC Working Group for PTH | 1.6 | 62 | Citations (PDF) |
| 199 | Vitamin K plasma levels determination in human health | 2.4 | 118 | Citations (PDF) |
| 200 | Bone markers during acute burn care: Relevance to clinical practice? | 2.3 | 5 | Citations (PDF) |
| 201 | Analytical and clinical validation of the new Abbot Architect 25(OH)D assay: fit for purpose? | 2.4 | 21 | Citations (PDF) |
| 202 | General Steps to Standardize the Laboratory Measurement of Serum Total 25-Hydroxyvitamin D | 1.7 | 58 | Citations (PDF) |
| 203 | Baseline Assessment of 25-Hydroxyvitamin D Assay Performance: A Vitamin D Standardization Program (VDSP) Interlaboratory Comparison Study | 1.7 | 51 | Citations (PDF) |
| 204 | Impact of the Type of Dialysis Membranes on the Circulating Concentration of Markers of Vitamin D Metabolism | 1.3 | 10 | Citations (PDF) |
| 205 | Baseline Assessment of 25-Hydroxyvitamin D Reference Material and Proficiency Testing/External Quality Assurance Material Commutability: A Vitamin D Standardization Program Study | 1.7 | 26 | Citations (PDF) |
| 206 | Sunscreens block cutaneous vitamin D production with only a minimal effect on circulating 25-hydroxyvitamin D | 2.6 | 35 | Citations (PDF) |
| 207 | Assessment of vitamin D status – a changing landscape | 2.4 | 194 | Citations (PDF) |
| 208 | A Randomised, Cross-Over Study to Estimate the Influence of Food on the 25-Hydroxyvitamin D3 Serum Level after Vitamin D3 Supplementation | 4.7 | 6 | Citations (PDF) |
| 209 | A paperless autoimmunity laboratory: myth or reality? | 0.1 | 4 | Citations (PDF) |
| 210 | Determination of iohexol and iothalamate in serum and urine by capillary electrophoresis | 2.6 | 7 | Citations (PDF) |
| 211 | Reference Method and Reference Material Are Necessary Tools to Reveal the Variability of Cystatin C Assays | 2.5 | 8 | Citations (PDF) |
| 212 | The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club | 4.2 | 53 | Citations (PDF) |
| 213 | Fibroblast growth factor 23 in acute burn patients: Novel insights from an intact-form assayBurns, 2016, 42, 1082-1087 | 2.3 | 7 | Citations (PDF) |
| 214 | Critical analytical evaluation of promising markers for sarcopenia | 2.6 | 10 | Citations (PDF) |
| 215 | Cystatin C standardization decreases assay variation and improves assessment of glomerular filtration rate | 1.6 | 40 | Citations (PDF) |
| 216 | Prevalence and determinants of vitamin D deficiency in healthy French adults: the VARIETE study | 2.6 | 65 | Citations (PDF) |
| 217 | Inadéquation du facteur ethnique pour l’estimation du débit de filtration glomérulaire en population générale noire-africaine : résultats en Côte d’Ivoire | 0.2 | 6 | Citations (PDF) |
| 218 | Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol? | 3.6 | 213 | Citations (PDF) |
| 219 | Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol? | 3.6 | 181 | Citations (PDF) |
| 220 | Sarcopenia in daily practice: assessment and management | 3.4 | 696 | Citations (PDF) |
| 221 | A simple LC-MS method for the determination of iohexol and iothalamate in serum, using ioversol as an internal standard | 1.6 | 15 | Citations (PDF) |
| 222 | The cardiovascular impact of intense eccentric isokinetic exercise versus aerobic treadmill running | 0.5 | 0 | Citations (PDF) |
| 223 | Determinants of vitamin D supplementation prescription in nursing homes: a survey among general practitioners | 4.2 | 13 | Citations (PDF) |
| 224 | When obtaining a blood sample from the right arm was not the right thing to do: a case of elevated parathyroid hormone levels 27 years after thyroidectomy | 2.4 | 0 | Citations (PDF) |
| 225 | Adaptation posologique des médicaments et fonction rénale : quel(s) estimateur(s) faut-il choisir ? | 0.2 | 9 | Citations (PDF) |
| 226 | Persistent low levels of serum hCG due to heterophilic mouse antibodies: an unrecognized pitfall in the diagnosis of trophoblastic disease | 1.9 | 7 | Citations (PDF) |
| 227 | Performance characteristics of the VIDAS® 25-OH Vitamin D Total assay – comparison with four immunoassays and two liquid chromatography-tandem mass spectrometry methods in a multicentric study | 2.4 | 32 | Citations (PDF) |
| 228 | How the reference values for serum parathyroid hormone concentration are (or should be) established? | 3.0 | 54 | Citations (PDF) |
| 229 | Vitamin D measurement: pre-analytical and analytical considerations | 0.1 | 3 | Citations (PDF) |
| 230 | New biomarkers for primary mitral regurgitation | 3.0 | 18 | Citations (PDF) |
| 231 | Cardiovascular calcification inhibitors | 0.1 | 4 | Citations (PDF) |
| 232 | A Randomized, Double-Blind, Parallel Study to Evaluate the Dose-Response of Three Different Vitamin D Treatment Schemes on the 25-Hydroxyvitamin D Serum Concentration in Patients with Vitamin D Deficiency | 4.7 | 23 | Citations (PDF) |
| 233 | Pathophysiological mechanisms of vascular calcification | 0.1 | 7 | Citations (PDF) |
| 234 | SP237DISCREPANCIES BETWEEN URINARY AND PLASMA NGAL CONCENTRATIONS IN PATIENTS ADMITTED TO THE MEDICAL INTENSIVE CARE | 0.8 | 0 | Citations (PDF) |
| 235 | Biomarkers of vascular calcifications: the osteoprotegerin/RANK/RANK L axis | 0.1 | 1 | Citations (PDF) |
| 236 | Vascular calcifications: can the biologist be of some help? | 0.1 | 0 | Citations (PDF) |
| 237 | Vitamin D status after a high dose of cholecalciferol in healthy and burn subjectsBurns, 2015, 41, 1028-1034 | 2.3 | 21 | Citations (PDF) |
| 238 | Impact of stopping vitamin K antagonist therapy on concentrations of dephospho-uncarboxylated Matrix Gla protein | 2.4 | 14 | Citations (PDF) |
| 239 | Considerations in parathyroid hormone testing | 2.4 | 28 | Citations (PDF) |
| 240 | Analytical and clinical evaluation of the new Fujirebio Lumipulse®G non-competitive assay for 25(OH)-vitamin D and three immunoassays for 25(OH)D in healthy subjects, osteoporotic patients, third trimester pregnant women, healthy African subjects, hemodialyzed and intensive care patients | 2.4 | 38 | Citations (PDF) |
| 241 | Serum calcitriol concentrations measured with a new direct automated assay in a large population of adult healthy subjects and in various clinical situations | 1.6 | 37 | Citations (PDF) |
| 242 | Measurement of circulating 25-hydroxyvitamin D: A historical review | 1.1 | 48 | Citations (PDF) |
| 243 | Effects of cholecalciferol supplementation and optimized calcium intakes on vitamin D status, muscle strength and bone health: A one-year pilot randomized controlled trial in adults with severe burns | 2.3 | 49 | Citations (PDF) |
| 244 | Laboratory challenges in primary aldosteronism screening and diagnosis | 1.9 | 82 | Citations (PDF) |
| 245 | Place de la vitamine D native en dialyse | 0.2 | 5 | Citations (PDF) |
| 246 | Vitamin D deficiency is common among adults in Wallonia (Belgium, 51°30′ North): findings from the Nutrition, Environment and Cardio-Vascular Health study | 2.8 | 26 | Citations (PDF) |
| 247 | How to manage an isolated elevated PTH? | 0.3 | 29 | Citations (PDF) |
| 248 | L’éveil de la matrix-gla-protéine sonnera le glas des calcifications vasculaires | 0.2 | 6 | Citations (PDF) |
| 249 | Problems with the PTH assays | 0.3 | 30 | Citations (PDF) |
| 250 | A phase IV, two-armed, randomized, cross-over study comparing compliance with once-a-month administration of vitamin D3 to compliance with daily administration of a fixed-dose combination of vitamin D3 and calcium during two 6-month periods | 4.2 | 9 | Citations (PDF) |
| 251 | A Renin-ssance in Primary Aldosteronism Testing: Obstacles and Opportunities for Screening, Diagnosis, and Management | 1.1 | 20 | Citations (PDF) |
| 252 | Épidémiologie de la lithiase urinaire en Belgique sur base d’une classification morpho-constitutionnelle | 0.2 | 21 | Citations (PDF) |
| 253 | Identification of cardiac repercussions after intense and prolonged concentric isokinetic exercise in young sedentary people | 1.2 | 5 | Citations (PDF) |
| 254 | Biomarkers and physiopathology in the cardiorenal syndrome | 1.6 | 33 | Citations (PDF) |
| 255 | Vascular calcification: from pathophysiology to biomarkers | 1.6 | 214 | Citations (PDF) |
| 256 | Efficiency of delivery observed treatment in hemodialysis patients: the example of the native vitamin D therapy | 1.6 | 6 | Citations (PDF) |
| 257 | Dephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients | 2.2 | 108 | Citations (PDF) |
| 258 | Is isokinetic eccentric exercise dangerous for the heart? | 0.5 | 3 | Citations (PDF) |
| 259 | Standardization of DiaSorin and Roche automated third generation PTH assays with an International Standard: impact on clinical populations | 2.4 | 25 | Citations (PDF) |
| 260 | Inter-method variability in bone alkaline phosphatase measurement: Clinical impact on the management of dialysis patients | 1.9 | 40 | Citations (PDF) |
| 261 | Comprehensive plasma profiling for the characterization of graft-versus-host disease biomarkers | 5.9 | 11 | Citations (PDF) |
| 262 | Prevalence of vitamin D inadequacy in European women aged over 80 years | 3.6 | 41 | Citations (PDF) |
| 263 | Detection of decreased glomerular filtration rate in intensive care units: serum cystatin C versusserum creatinine | 2.2 | 76 | Citations (PDF) |
| 264 | Effect of cholecalciferol recommended daily allowances on vitamin D status and fibroblast growth factor-23: An observational study in acute burn patients | 2.3 | 32 | Citations (PDF) |
| 265 | Vitamin D status of schoolchildren in Northern Algeria, seasonal variations and determinants of vitamin D deficiency | 4.2 | 46 | Citations (PDF) |
| 266 | Evaluation of automated immunoassays for 25(OH)-vitamin D determination in different critical populations before and after standardization of the assays | 1.6 | 73 | Citations (PDF) |
| 267 | Enzymatic creatinine assays allow estimation of glomerular filtration rate in stages 1 and 2 chronic kidney disease using CKD-EPI equation | 1.6 | 34 | Citations (PDF) |
| 268 | The Third/Second Generation PTH Assay Ratio as a Marker for Parathyroid Carcinoma: Evaluation Using an Automated Platform | 4.2 | 41 | Citations (PDF) |
| 269 | Critical care and vitamin D status assessment: What about immunoassays and calculated free 25OH-D? | 1.6 | 28 | Citations (PDF) |
| 270 | Evaluation of circulating irisin levels in healthy young individuals after a single 100,000IU vitamin D dose | 0.3 | 11 | Citations (PDF) |
| 271 | Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts | 0.8 | 50 | Citations (PDF) |
| 272 | The Effects of Vitamin D on Skeletal Muscle Strength, Muscle Mass, and Muscle Power: A Systematic Review and Meta-Analysis of Randomized Controlled Trials | 4.2 | 597 | Citations (PDF) |
| 273 | Calibration and precision of serum creatinine and plasma cystatin C measurement: impact on the estimation of glomerular filtration rate | 1.6 | 79 | Citations (PDF) |
| 274 | Creatinine-or cystatin C-based equations to estimate glomerular filtration in the general population: impact on the epidemiology of chronic kidney disease | 2.2 | 27 | Citations (PDF) |
| 275 | GFR Estimation Using Standardized Cystatin C in Kidney Transplant Recipients | 1.4 | 62 | Citations (PDF) |
| 276 | Vitamine D et rein | 2.7 | 5 | Citations (PDF) |
| 277 | Modification of Diet in Renal Disease versus Chronic Kidney Disease Epidemiology Collaboration equation to estimate glomerular filtration rate in obese patients | 0.8 | 34 | Citations (PDF) |
| 278 | Technical and clinical evaluation of the VITROS<sup>®</sup> Immunodiagnostic Products 25-OH Vitamin D Total Assay – comparison with marketed automated immunoassays and a liquid chromatography-tandem mass spectrometry method | 2.4 | 12 | Citations (PDF) |
| 279 | Identification of protein biomarkers associated with cardiac ischemia by a proteomic approach | 2.0 | 3 | Citations (PDF) |
| 280 | EVOLVE : entre déception et optimisme | 0.2 | 1 | Citations (PDF) |
| 281 | Parathormone and bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients: Is it so simple? | 1.6 | 6 | Citations (PDF) |
| 282 | Enzymatic but not compensated Jaffe methods reach the desirable specifications of NKDEP at normal levels of creatinine. Results of the French multicentric evaluation | 1.6 | 63 | Citations (PDF) |
| 283 | Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study | 0.8 | 76 | Citations (PDF) |
| 284 | A Randomised, Double-Blinded, Placebo-Controlled, Parallel Study of Vitamin D3 Supplementation with Different Schemes Based on Multiples of 25,000 IU Doses | 2.0 | 10 | Citations (PDF) |
| 285 | Staging chronic kidney disease and estimating glomerular filtration rate: an opinion paper about the new international recommendations | 2.4 | 16 | Citations (PDF) |
| 286 | IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children | 2.4 | 47 | Citations (PDF) |
| 287 | MDRD Versus CKD-EPI Equation to Estimate Glomerular Filtration Rate in Kidney Transplant Recipients | 1.2 | 91 | Citations (PDF) |
| 288 | Supplementation, Optimal Status, and Analytical Determination of Vitamin D: Where are we Standing in 2012? | 2.2 | 7 | Citations (PDF) |
| 289 | The effects of vitamin D on skeletal muscle strength: a meta-analysis of randomized controlled trials | 0.3 | 0 | Citations (PDF) |
| 290 | Normal reference values for glomerular filtration rate: what do we really know? | 0.8 | 139 | Citations (PDF) |
| 291 | Evaluation of the cross-reactivity of 25-hydroxyvitamin D2 on seven commercial immunoassays on native samples | 2.4 | 29 | Citations (PDF) |
| 292 | Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values | 0.8 | 77 | Citations (PDF) |
| 293 | Outcome of the living kidney donor | 0.8 | 72 | Citations (PDF) |
| 294 | Effects of Large‐Pore Hemofiltration in a Swine Model of Fulminant Hepatic Failure | 1.8 | 4 | Citations (PDF) |
| 295 | Analytical evaluation of the new Abbott Architect 25-OH vitamin D assay | 1.9 | 23 | Citations (PDF) |
| 296 | Le dosage des acides gras érythrocytaires : comparaison entre une population de référence et des sujets ayant présenté un infarctus aigu du myocarde | 0.1 | 0 | Citations (PDF) |
| 297 | Suivi biologique du métabolisme phosphocalcique chez le patient dialysé : que nous apportent les guidelines du KDIGO en pratique ? | 0.1 | 1 | Citations (PDF) |
| 298 | L’estimation du débit de filtration glomérulaire en 2012 : quelle valeur ajoutée pour la nouvelle équation CKD-EPI ? | 0.2 | 12 | Citations (PDF) |
| 299 | NGAL, biomarqueur de lésion rénale : point d’étape en 2012 | 0.2 | 10 | Citations (PDF) |
| 300 | Vitamin D and primary hyperparathyroidism (PHPT) | 0.3 | 21 | Citations (PDF) |
| 301 | Distinctive Aspects of Laboratory Testing to Evaluate Mineral and Bone Metabolism in Patients with Chronic Kidney Disease | 2.3 | 2 | Citations (PDF) |
| 302 | Comparison of acid and enzymatic methods for inulin dosage: Analytical performances and impact on glomerular filtration rate evaluation | 1.6 | 12 | Citations (PDF) |
| 303 | Demystifying ethnic/sex differences in kidney function: Is the difference in (estimating) glomerular filtration rate or in serum creatinine concentration? | 1.6 | 35 | Citations (PDF) |
| 304 | Aberrant results observed with four immuno-assays for total and free prostate-specific antigen (PSA) determination: a case-report | 2.4 | 4 | Citations (PDF) |
| 305 | A new tool in the field of in-vitro diagnosis of allergy: preliminary results in the comparison of ImmunoCAP<sup>©</sup> 250 with the ImmunoCAP<sup>©</sup> ISAC | 2.4 | 73 | Citations (PDF) |
| 306 | A multicentric evaluation of IDMS-traceable creatinine enzymatic assays | 1.6 | 124 | Citations (PDF) |
| 307 | Vitamin D and type 2 diabetes mellitus: Where do we stand? | 3.6 | 44 | Citations (PDF) |
| 308 | Tumor-induced osteomalacia: The tumor may stay hidden! | 1.9 | 14 | Citations (PDF) |
| 309 | Recommendations for the selection and alignment techniques for the determination of creatinine | 0.1 | 4 | Citations (PDF) |
| 310 | Measurement of inulin: development | 0.1 | 8 | Citations (PDF) |
| 311 | Vitamin D, cardiovascular disease and mortality | 2.5 | 211 | Citations (PDF) |
| 312 | Overestimation of the 25(OH)D serum concentration with the automated IDS EIA kit | 5.0 | 14 | Citations (PDF) |
| 313 | Cystatin C is a reliable marker for estimation of glomerular filtration rate in renal transplantation: validation of a new turbidimetric assay using monospecific sheep antibodies | 2.4 | 10 | Citations (PDF) |
| 314 | Are the Creatinine-Based Equations Accurate to Estimate Glomerular Filtration Rate in African American Populations? | 4.4 | 72 | Citations (PDF) |
| 315 | Neutrophil gelatinase-associated lipocalin (NGAL) determined in urine with the Abbott Architect or in plasma with the Biosite Triage? The laboratory's point of view | 2.4 | 30 | Citations (PDF) |
| 316 | Cross-reactivity of 25-hydroxy vitamin D2 from different commercial immunoassays for 25-hydroxy vitamin D: an evaluation without spiked samples | 2.4 | 27 | Citations (PDF) |
| 317 | Analytical validation of the Liaison Calcitonin_II-Gen (DiaSorin) | 2.4 | 6 | Citations (PDF) |
| 318 | Estimating glomerular filtration rate in Asian subjects: where do we stand? | 5.0 | 26 | Citations (PDF) |
| 319 | La créatinine: d'hier à aujourd'hui | 0.1 | 15 | Citations (PDF) |
| 320 | Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice | 7.5 | 488 | Citations (PDF) |
| 321 | MDRD or CKD-EPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant? | 2.2 | 50 | Citations (PDF) |
| 322 | Analytical validation of serum bone alkaline phosphatase (BAP OSTASE) on Liaison | 2.4 | 16 | Citations (PDF) |
| 323 | Interpretation of serum parathyroid hormone concentrations in dialysis patients: what do the KDIGO guidelines change for the clinical laboratory? | 2.4 | 19 | Citations (PDF) |
| 324 | Reply | 0.8 | 0 | Citations (PDF) |
| 325 | The Ratio of Parathyroid Hormone as Measured by Third- and Second-Generation Assays as a Marker for Parathyroid Carcinoma | 4.2 | 61 | Citations (PDF) |
| 326 | An unusual interference in parathormone assay caused by anti-goat IgG: a case report | 2.4 | 2 | Citations (PDF) |
| 327 | Vitamin D: current status and perspectives | 2.4 | 65 | Citations (PDF) |
| 328 | Estimation of the Stability of Parathyroid Hormone when Stored at −80°C for a Long Period | 4.4 | 27 | Citations (PDF) |
| 329 | Low prevalence of chronic kidney disease in Far-East Asian populations: impact of the ethnicity factor? | 0.8 | 2 | Citations (PDF) |
| 330 | Discrepancies between creatinine‐based and cystatin C‐based equations in estimating prevalence of stage 3 chronic kidney disease in an elderly population | 1.3 | 17 | Citations (PDF) |
| 331 | Actualité sur les effets de la vitamine D et l’évaluation du statut vitaminique D | 0.1 | 3 | Citations (PDF) |
| 332 | Defining a “Reference Population”: No Easy Task | 5.0 | 8 | Citations (PDF) |
| 333 | Errors induced by indexing glomerular filtration rate for body surface area: reductio ad absurdum | 0.8 | 71 | Citations (PDF) |
| 334 | La vitamine D : effets « classiques », « non classiques » et évaluation du statut du patient | 0.0 | 2 | Citations (PDF) |
| 335 | Indexation du débit de filtration glomérulaire par la surface corporelle : mythe et réalité | 0.2 | 11 | Citations (PDF) |
| 336 | Human Anti-Mouse Antibodies Interferences in Elecsys PTH Assay After OKT3 Treatment | 1.2 | 12 | Citations (PDF) |
| 337 | Measurement uncertainty of 25-OH vitamin D determination with different commercially available kits: impact on the clinical cut offs | 4.2 | 39 | Citations (PDF) |
| 338 | Measurement uncertainty for the analysis of serum 25-hydroxyvitamin D: response to Stepman and Thienpont | 4.2 | 0 | Citations (PDF) |
| 339 | Estimation of GFR by different creatinine- and cystatin-C-based equations in anorexia nervosa | 0.8 | 26 | Citations (PDF) |
| 340 | Cystatin C-based equations: don't repeat the same errors with analytical considerations | 0.8 | 11 | Citations (PDF) |
| 341 | Serum Vitamin D Measurement May Not Reflect What You Give to Your Patients | 5.0 | 35 | Citations (PDF) |
| 342 | Actualité sur les effets de la vitamine D et l’évaluation du statut vitaminique D | 0.3 | 50 | Citations (PDF) |
| 343 | Déficit en vitamine D chez l’homme âgé vivant à domicile ou en institution en milieu urbain | 2.7 | 9 | Citations (PDF) |
| 344 | Vitamine D2 ou vitamine D3 ? | 0.1 | 20 | Citations (PDF) |
| 345 | False positive PTH results: An easy strategy to test and detect analytical interferences in routine practice | 1.6 | 40 | Citations (PDF) |
| 346 | Performance of iohexol determination in serum and urine by HPLC: Validation, risk and uncertainty assessment | 1.6 | 68 | Citations (PDF) |
| 347 | Analytical study of three cystatin C assays and their impact on cystatin C-based GFR-prediction equations | 1.6 | 55 | Citations (PDF) |
| 348 | Reproducibility of GFR measured by chromium-51-EDTA and iohexol | 0.8 | 17 | Citations (PDF) |
| 349 | Analytical Quality of Calcitonin Determination and Its Effect on the Adequacy of Screening for Medullary Carcinoma of the Thyroid | 1.1 | 18 | Citations (PDF) |
| 350 | Analytical Variation in Plasma Renin Activity: Implications for the Screening of Primary Aldosteronism | 1.1 | 3 | Citations (PDF) |
| 351 | Analytical validation of the new version of the Liaison N-Tact PTH assay | 2.4 | 7 | Citations (PDF) |
| 352 | The RIFLE criteria: Are the foundations robust? | 0.5 | 1 | Citations (PDF) |
| 353 | Intravenous iron therapy restores functional iron deficiency induced by infliximab | 1.3 | 21 | Citations (PDF) |
| 354 | Evaluation of different bone markers in hemodialyzed patients | 1.6 | 16 | Citations (PDF) |
| 355 | Creatinine-based formulae for the estimation of glomerular filtration rate in heart transplant recipients | 1.7 | 40 | Citations (PDF) |
| 356 | Importance of the creatinine calibration in the estimation of GFR by MDRD equation | 0.8 | 9 | Citations (PDF) |
| 357 | Renal extraction of cystatin C | 0.8 | 4 | Citations (PDF) |
| 358 | Analytical validation of the new plasma calibrated Accu-Chek® Test Strips (Roche Diagnostics) | 2.4 | 19 | Citations (PDF) |
| 359 | Why the MDRD equation should not be used in patients with normal renal function (and normal creatinine values)? | 0.8 | 41 | Citations (PDF) |
| 360 | Comparison of Liaison N-tact PTH (Diasorin) and N-tact PTH SP IRMA (Diasorin) in hemodialyzed patients | 2.4 | 4 | Citations (PDF) |
| 361 | Abnormal response to metabolic stress in schizophrenia: marker of vulnerability or acquired sensitization? | 4.2 | 47 | Citations (PDF) |
